180 Life Sciences Recommendation mean
What is the Recommendation mean of 180 Life Sciences?
The Recommendation mean of 180 Life Sciences Corp. is 2.50
What is the definition of Recommendation mean?
Recommendation mean is the mean of analysts’ ratings of the stock ranging from 1.0 (strong buy) to 5.0 (strong sell).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Recommendation mean of companies in the Health Care sector on NASDAQ compared to 180 Life Sciences
What does 180 Life Sciences do?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Companies with recommendation mean similar to 180 Life Sciences
- Revvity has Recommendation mean of 2.47
- Cardinal Health has Recommendation mean of 2.47
- Cintas has Recommendation mean of 2.47
- Textron has Recommendation mean of 2.47
- Ralph Lauren Corp has Recommendation mean of 2.48
- NOV Inc has Recommendation mean of 2.48
- 180 Life Sciences has Recommendation mean of 2.50
- Landbridge has Recommendation mean of 2.52
- Urban Outfitters has Recommendation mean of 2.52
- Wells Fargo & Co has Recommendation mean of 2.52
- United Airlines Inc has Recommendation mean of 2.52
- Cognizant Technology Solutions has Recommendation mean of 2.52
- Grupo Aeroportuario Del Pacifico SAB de CV has Recommendation mean of 2.53